Table 1.
Clinical and pathological characteristics of the study population (n = 24).
| Patients | Intestinal (n = 12) | Diffuse (n = 12) | P |
|---|---|---|---|
| Age* | 72.2 ± 5.6 | 71.7 ± 12.5 | N.S. |
| Gender: | |||
| • M • F |
9 (75%) 3 (25%) |
6 (50%) 6 (50%) |
N.S. |
| pT: | |||
| • 1 • 2 • 3 • 4 |
0 0 6 (50%) 6 (50%) |
0 1 (8.3%) 5 (41.7%) 6 (50%) |
N.S. |
| pN: | |||
| • N0 • N1 • N2 • N3 |
1 (8.3%) 1 (8.3%) 3 (25%) 7 (58.4) |
1 (8.3%) 0 4 (33.3%) 7 (58.4) |
N.S. |
| Stage: | |||
| • I • II • III • IV |
0 1 (8.3%) 8 (66.7%) 3(25%) |
0 0 6 (50%) 6 (50%) |
N.S. |
| Lymphonodal Harvested**: | 38.5 | 37 | N.S. |
| Lymphonodal Ratio** | 0.2 | 0.3 | N.S. |
| Tumor Location: | |||
| * U * M * L |
2 (16.7%) 6 (50%) 4 (33.3%) |
4 (33.3%) 5 (41.7%) 3 (25%) |
N.S. |
| Lymphoadenectomy: | |||
| * D1 * D2 * D3 |
1 (8.3%) 11 (91.7%) 0 |
2 (16.7%) 9 (75%) 1 (8.3%) |
N.S. |
| Multiorgan resection: | 2 (16.7%) | 3 (25%) | N.S. |
| Peritoneal Carcinomatosis development: | 4 (33.3%) | 8 (66.6%) | N.S. |
| N/L ratio**: | 2.3 | 3.5 | N.S. |
| Sieric Albumin*** | 3.5 | 3.5 | N.S. |
*Mean ± Dev. St.
**Median value.
***deviation from the physiological value.
N.S., not statistical.